Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
Serina Therapeutics (NYSE: SER) has secured $5 million in strategic funding to advance its lead clinical candidate SER-252 for Advanced Parkinson's disease. The financing involves issuing 965,250 shares of convertible preferred stock at $5.18 per share.
The funds will support the development of SER-252 (POZ-apomorphine), which utilizes Serina's proprietary POZ Platform™ drug optimization technology. The company aims to initiate a Phase 1 clinical trial in the fourth quarter of 2025. The therapeutic approach focuses on achieving continuous dopaminergic stimulation for potential clinical benefits in advanced Parkinson's disease patients.
Serina Therapeutics (NYSE: SER) ha ottenuto 5 milioni di dollari in finanziamenti strategici per avanzare il suo principale candidato clinico SER-252 per il morbo di Parkinson avanzato. Il finanziamento prevede l'emissione di 965.250 azioni di azioni privilegiate convertibili a 5,18 dollari per azione.
I fondi supporteranno lo sviluppo di SER-252 (POZ-apomorfina), che utilizza la tecnologia proprietaria di ottimizzazione dei farmaci POZ Platform™ di Serina. L'azienda punta a avviare un trial clinico di Fase 1 nel quarto trimestre del 2025. L'approccio terapeutico si concentra sul raggiungimento di una stimolazione dopaminergica continua per potenziali benefici clinici nei pazienti con morbo di Parkinson avanzato.
Serina Therapeutics (NYSE: SER) ha asegurado 5 millones de dólares en financiamiento estratégico para avanzar su principal candidato clínico SER-252 para la enfermedad de Parkinson avanzada. El financiamiento implica la emisión de 965,250 acciones de acciones preferentes convertibles a 5.18 dólares por acción.
Los fondos apoyarán el desarrollo de SER-252 (POZ-apomorfina), que utiliza la tecnología de optimización de medicamentos POZ Platform™ de Serina. La compañía tiene como objetivo iniciar un ensayo clínico de Fase 1 en el cuarto trimestre de 2025. El enfoque terapéutico se centra en lograr una estimulación dopaminérgica continua para posibles beneficios clínicos en pacientes con enfermedad de Parkinson avanzada.
세리나 테라퓨틱스 (NYSE: SER)는 고급 파킨슨병을 위한 주요 임상 후보인 SER-252를 발전시키기 위해 500만 달러의 전략적 자금을 확보했습니다. 이번 자금 조달은 주당 5.18달러에 965,250주의 전환 우선주를 발행하는 것을 포함합니다.
이 자금은 세리나의 독점 POZ 플랫폼™ 약물 최적화 기술을 활용하는 SER-252 (POZ-아포모르핀)의 개발을 지원합니다. 회사는 2025년 4분기에 1상 임상 시험을 시작할 계획입니다. 치료 접근법은 고급 파킨슨병 환자에게 잠재적인 임상 혜택을 위한 지속적인 도파민 자극을 달성하는 데 중점을 두고 있습니다.
Serina Therapeutics (NYSE: SER) a obtenu 5 millions de dollars de financement stratégique pour faire avancer son principal candidat clinique SER-252 pour la maladie de Parkinson avancée. Le financement implique l'émission de 965 250 actions d'actions privilégiées convertibles à 5,18 dollars par action.
Les fonds soutiendront le développement de SER-252 (POZ-apomorphine), qui utilise la technologie d'optimisation des médicaments POZ Platform™ de Serina. L'entreprise vise à initier un essai clinique de phase 1 au quatrième trimestre de 2025. L'approche thérapeutique se concentre sur l'obtention d'une stimulation dopaminergique continue pour des bénéfices cliniques potentiels chez les patients atteints de la maladie de Parkinson avancée.
Serina Therapeutics (NYSE: SER) hat 5 Millionen Dollar an strategischer Finanzierung gesichert, um seinen führenden klinischen Kandidaten SER-252 für fortgeschrittene Parkinson-Krankheit voranzutreiben. Die Finanzierung umfasst die Ausgabe von 965.250 Aktien von wandelbaren Vorzugsaktien zu je 5,18 Dollar pro Aktie.
Die Mittel werden die Entwicklung von SER-252 (POZ-Apomorphin) unterstützen, das die proprietäre POZ Platform™-Technologie zur Arzneimitteloptimierung von Serina nutzt. Das Unternehmen plant, im vierten Quartal 2025 eine Phase-1-Studie zu starten. Der therapeutische Ansatz konzentriert sich darauf, eine kontinuierliche dopaminerge Stimulation zu erreichen, um potenzielle klinische Vorteile für Patienten mit fortgeschrittener Parkinson-Krankheit zu erzielen.
- Secured $5 million in strategic funding
- Advancing to Phase 1 clinical trials in Q4 2025
- Stock price maintained at $5.18 per share for preferred stock issuance
- Dilution of existing shareholders through issuance of 965,250 new convertible preferred shares
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a
“This financing further strengthens our cash position and reflects the confidence of our strategic investors in the potential of SER-252,” said Steve Ledger, CEO of Serina Therapeutics. “With a novel approach to achieving continuous dopaminergic stimulation, we believe SER-252 may offer meaningful clinical benefit to patients with advanced Parkinson’s disease. We remain focused on initiating first-in-human studies later this year.”
In connection with the financing, Serina issued 965,250 shares of convertible preferred stock at
About SER-252 (POZ-apomorphine)
SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) and enable greater on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse™ wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection without skin reactions.
About the POZ Platform™
Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K, and Serina’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
How much funding did Serina Therapeutics (SER) raise in April 2025?
When will Serina Therapeutics (SER) begin Phase 1 trials for SER-252?
What is the therapeutic target of Serina's SER-252 drug candidate?
How many preferred shares did Serina (SER) issue in the April 2025 financing?
